These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24281197)

  • 21. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.
    Calascibetta A; Cabibi D; Martorana A; Sanguedolce G; Rausa L; Feo S; Dardanoni G; Sanguedolce R
    Anticancer Res; 2004; 24(6):3875-80. PubMed ID: 15736425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
    Yamada H; Ichikawa W; Uetake H; Shirota Y; Nihei Z; Sugihara K; Hirayama R
    Clin Colorectal Cancer; 2001 Nov; 1(3):169-73; discussion 174. PubMed ID: 12450430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
    Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
    Kakimoto M; Uetake H; Osanai T; Shirota Y; Takagi Y; Takeshita E; Toriya Y; Danenberg K; Danenberg PV; Sugihara K
    Cancer Lett; 2005 Jun; 223(1):103-11. PubMed ID: 15890242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.
    Gomez HL; Santillana SL; Vallejos CS; Velarde R; Sanchez J; Wang X; Bauer NL; Hockett RD; Chen VJ; Niyikiza C; Hanauske AR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):832-8. PubMed ID: 16467096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thymidylate synthase as a predictor of response.
    Leichman CG
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):43-7. PubMed ID: 9726090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
    Lenz HJ; Hayashi K; Salonga D; Danenberg KD; Danenberg PV; Metzger R; Banerjee D; Bertino JR; Groshen S; Leichman LP; Leichman CG
    Clin Cancer Res; 1998 May; 4(5):1243-50. PubMed ID: 9607583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.
    Fakhrejahani E; Miyamoto A; Tanigawa N
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):437-46. PubMed ID: 17377791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
    Eismann U; Oberschmidt O; Ehnert M; Fleeth J; Lüdtke FE; Struck S; Schulz L; Blatter J; Lahn MM; Ma D; Niyikiza C; Paoletti P; Hanauske AR
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):567-9. PubMed ID: 16372519
    [No Abstract]   [Full Text] [Related]  

  • 32. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma.
    Moreira LR; Schenka AA; Latuff Filho P; Nascimento H; Passos Lima CS; Silva Trevisan MA; Vassallo J
    Int J Surg Pathol; 2009 Jun; 17(3):181-6. PubMed ID: 19147506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
    Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
    Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
    Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
    Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymidylate synthase pharmacogenetics in colorectal cancer.
    Marsh S; McLeod HL
    Clin Colorectal Cancer; 2001 Nov; 1(3):175-8; discussion 179-81. PubMed ID: 12450432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
    Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E
    Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.